Source: Eur Respir J 2011; 38: 1036-1043
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Dijkstra A., Postma D.S., Bruinenberg M., van Diemen C.C., Boezen H.M., Koppelman G.H., Timens W., Vonk J.M.. SERPINE1 -675 4G/5G polymorphism is associated with asthma severity and inhaled corticosteroid response. Eur Respir J 2011; 38: 1036-1043

Member's Comments

No comment yet.

Related content which might interest you: Soluble urokinase-type plasminogen activator receptor is a novel biomarker predicting acute exacerbation in COPD Source: International Congress 2015 – Non-exhaled biomarkers in the assessment of airways disease Year: 2015 Urokinase plasminogen activator receptor polymorphisms and airway remodelling in asthma Source: Eur Respir J 2016; 47:1568-1571 Year: 2016 Relationship of circulating soluble urokinase plasminogen activator receptor (suPAR) levels to disease control in asthma and asthmatic pregnancy Source: International Congress 2014 – Systemic biomarkers for airway diseases Year: 2014 E-cadherin gene polymorphisms in asthma patients using inhaled corticosteroids Source: Eur Respir J 2011; 38: 1044-1052 Year: 2011 Urokinase type plasminogen activator improves airway inflammation and mucin expression in a murine asthma model Source: Annual Congress 2010 - Mechanisms and modulation of allergic inflammation in the lung Year: 2010 The relation between plasminogen activator inhibitor-1 (PAI-1) and inflammatory markers in COPD: A possible risk factor of inflammation-induced thrombosis Source: International Congress 2017 – Systemic and airway biomarkers Year: 2017 Association of VEGF polymorphisms with childhood asthma, lung function and airway responsiveness Source: Eur Respir J 2009; 33: 1287-1294 Year: 2009 Platelet activating factor receptor (PAFr) expression is increased in airways of COPD patients but is not attenuated by inhaled corticosteroid (ICS) Source: Annual Congress 2013 –COPD: new markers of diseases Year: 2013 E-cadherin (CDH-1) polymorphisms associate with airway remodeling, inflammation and FEV1 decline in asthma patients using inhaled corticosteroids (ICS) Source: Annual Congress 2010 - The impact of genes and environment on obstructive airway diseases Year: 2010 Soluble urokinase-type plasminogen activator receptor in monitoring of treatment response in acute exacerbation of chronic obstructive pulmonary disease Source: International Congress 2017 – Current challenges in COPD evaluation Year: 2017 ADRB2 Gly16Arg polymorphism, asthma control and lung function decline Source: Eur Respir J 2011; 38: 1029-1035 Year: 2011 The role of glucocorticoid receptor a and ß isoforms in exacerbations of asthma, COPD, and ACOS Source: International Congress 2017 – Gene signatures in bronchial diseases Year: 2017 The new approaches to the oral corticosteroid dosage decrease in patients with severe steroid-resistant bronchial asthma Source: Annual Congress 2005 - Improving asthma control in the harder-to-reach population Year: 2005 Increased expression of ADRB2, CHRM3 and glucocorticoid alpha receptor genes in blood leukocytes of COPD patients Source: International Congress 2016 – Airway pharmacology: drug targets and mode of action Year: 2016 GLCCI1 variant accelerates pulmonary function decline in patients with asthma receiving inhaled corticosteroids Source: International Congress 2014 – Genetics and environmental factors underlying asthma and COPD Year: 2014 ADRB2R gene polymorphism (pol.) associated with the severity of cystic fibrosis(CF) and the effectiveness of the use of inhaled bronchodilator Source: Annual Congress 2010 - Cystic fibrosis: clinical and laboratory studies Year: 2010 Association of genetic variations of CC chemokine receptor-2 (CCR2) with atopic asthma, but not with nonatopic asthma Source: Annual Congress 2005 - Genetic polymorphisms and molecular mechanisms in asthma pathophysiology Year: 2005 Monitoring asthma and adjusting the inhaled steroid dose: is there a better way? Source: Annual Congress 2005 - Are we ready for "inflammometry"? The role of eNO in asthma management Year: 2005 The effect of the novel SHIP1 activator AQX-1125 on allergen-induced responses in mild to moderate asthma Source: Annual Congress 2013 –New drugs in respiratory medicine Year: 2013 Soluble urokinase plasminogen activator receptor (suPAR) predicts mortality in exacerbated COPD Source: International Congress 2018 – New predictors of morbidity and mortality in COPD Year: 2018